Compare Stocks: KMDA, IMCR, LKFT, and TSHA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$37.57 +0.5%	$34.39	$27.56 ▼ $40.71	$1.92B	0.74	387,231 shs	245,972 shs
KMDA Kamada	$8.27 -1.5%	$7.49	$6.50 ▼ $9.35	$483.04M	0.88	178,052 shs	112,127 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.02 +0.7%	$28.74	$25.68 ▼ $37.78	$1.90B	0.28	258,170 shs	394,298 shs
TSHA Taysha Gene Therapies	$5.57 -1.2%	$6.08	$2.71 ▼ $7.30	$1.84B	1.19	2.52 million shs	1.88 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	+0.54%	+2.23%	+13.03%	+32.80%	+6.52%
KMDA Kamada	-1.55%	+0.12%	+12.67%	+15.34%	+18.65%
LKFT Lakefront Biotherapeutics American Depositary Shares	+0.73%	-1.43%	+9.72%	+3.57%	-7.17%
TSHA Taysha Gene Therapies	-1.24%	-6.54%	-10.16%	+1.27%	+92.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$37.57 +0.5%	$34.39	$27.56 ▼ $40.71	$1.92B	0.74	387,231 shs	245,972 shs
KMDA Kamada	$8.27 -1.5%	$7.49	$6.50 ▼ $9.35	$483.04M	0.88	178,052 shs	112,127 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.02 +0.7%	$28.74	$25.68 ▼ $37.78	$1.90B	0.28	258,170 shs	394,298 shs
TSHA Taysha Gene Therapies	$5.57 -1.2%	$6.08	$2.71 ▼ $7.30	$1.84B	1.19	2.52 million shs	1.88 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	+0.54%	+2.23%	+13.03%	+32.80%	+6.52%
KMDA Kamada	-1.55%	+0.12%	+12.67%	+15.34%	+18.65%
LKFT Lakefront Biotherapeutics American Depositary Shares	+0.73%	-1.43%	+9.72%	+3.57%	-7.17%
TSHA Taysha Gene Therapies	-1.24%	-6.54%	-10.16%	+1.27%	+92.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMCR Immunocore	2.69	Moderate Buy	$56.38	50.05% Upside
KMDA Kamada	3.00	Buy	$13.00	57.19% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.33	Hold	$30.67	5.67% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	129.25% Upside

Current Analyst Ratings Breakdown

Latest KMDA, IMCR, LKFT, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/21/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$28.00 ➝ $26.00
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/5/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/3/2026	IMCR Immunocore	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$34.00 ➝ $35.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMCR Immunocore	$400.02M	4.84	N/A	N/A	$8.15 per share	4.61
KMDA Kamada	$180.46M	2.64	$0.60 per share	13.76	$4.69 per share	1.76
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$0.73 per share	39.68	$57.58 per share	0.50
TSHA Taysha Gene Therapies	$9.77M	185.76	N/A	N/A	$1.19 per share	4.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMCR Immunocore	-$35.51M	-$0.37	N/A	150.28	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	21.76	13.78	0.69	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest KMDA, IMCR, LKFT, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.57%	N/A	34.21%	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Latest KMDA, IMCR, LKFT, and TSHA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMCR Immunocore	0.94	4.47	4.44
KMDA Kamada	N/A	4.06	2.29
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMCR Immunocore	84.50%
KMDA Kamada	20.38%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
IMCR Immunocore	10.10%
KMDA Kamada	36.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMCR Immunocore	320	51.50 million	46.30 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
TSHA Taysha Gene Therapies	180	325.83 million	314.50 million	Optionable

KMDA, IMCR, LKFT, and TSHA Headlines

Recent News About These Companies

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

August 20, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

August 18, 2026 | marketbeat.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why

August 13, 2026 | marketbeat.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

August 12, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

July 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, IMCR, LKFT, and TSHA Company Descriptions

Immunocore NASDAQ:IMCR

$37.57 +0.20 (+0.54%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$37.56 -0.01 (-0.03%)

As of 04:14 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Kamada NASDAQ:KMDA

$8.27 -0.13 (-1.55%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$8.27 0.00 (-0.01%)

As of 04:21 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$29.02 +0.21 (+0.73%)

As of 09/3/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Taysha Gene Therapies NASDAQ:TSHA

$5.57 -0.07 (-1.24%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$5.69 +0.12 (+2.14%)

As of 05:10 AM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, IMCR, LKFT, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, IMCR, LKFT, and TSHA Earnings

Compare Dividends

Latest KMDA, IMCR, LKFT, and TSHA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, IMCR, LKFT, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, IMCR, LKFT, and TSHA Company Descriptions

Immunocore NASDAQ:IMCR

Kamada NASDAQ:KMDA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, IMCR, LKFT, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, IMCR, LKFT, and TSHA Earnings

Compare Dividends

Latest KMDA, IMCR, LKFT, and TSHA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, IMCR, LKFT, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, IMCR, LKFT, and TSHA Company Descriptions

Immunocore NASDAQ:IMCR

Kamada NASDAQ:KMDA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools